Abstract：Objective To investigate the effect of Methylprednisolone Sodium Succinate in the treatment of children with severe mycoplasma pneumonia and its effect on inflammatory factors. Methods A total of 100 children with severe mycoplasma pneumonia in Baoding Children’s Hospital of Heibei Province from October 2018 to September 2020 were selected as research objects，and they were divided into control group（conventional symptomatic treatment）and observation group（Methylprednisolone Sodium Succinate combined with conventional symptomatic treatment）, with 50 cases in each group according to the random number table method. The clinical total effective rate, improvement time of symptoms and signs (fever, cough and pulmonary ronal sound), the levels of serum proinflammatory factors (interleukin-1β [IL-1β], IL-6, and tumor necrosis factor-α [TNF-α]) and anti-inflammatory factors (IL-4 and γ interferon [IFN-γ]) before treatment, three and five days after treatment were compared between two groups. Results The clinical total effective rate of observation group were higher than those of control group， and the differences were statistically significant (P ＜ 0.05). The improvement time of symptoms and signs between two groups were statistically significant (P < 0.05). After three and five days of treatment, the levels of IL-1β, IL-6, TNF-α, IL-4, and IFN-γ in observation group were lower than those in control group, and the differences were statistically significant (P < 0.05). Conclusion Methylprednisolone Sodium Succinate combined with conventional symptomatic treatment has a good curative effect on children with severe mycoplasma pneumonia, and can effectively control the expression level of inflammatory factors in children, so the application value is relatively high.
刘晓萌1 张燕北2 于海明1 张贺1 孙媛媛2. 甲泼尼龙琥珀酸钠治疗儿童重症支原体肺炎的效果及对炎症因子的影响[J]. 中国医药导报, 2021, 18(29): 98-101.
LIU Xiaomeng1 ZHANG Yanbei2 YU Haiming1 ZHANG He1 SUN Yuanyuan2. Effect of Methylprednisolone Sodium Succinate in the treatment of children with severe mycoplasma pneumonia and its effect on inflammatory factors#br#. 中国医药导报, 2021, 18(29): 98-101.
[1] 赵悦彤.肺炎支原体肺炎常见远期并发症的研究进展[J].国际儿科学杂志，2019，46（1）：36-39.
[2] 叶菁.儿童肺炎支原体肺炎严重程度评估进展[J].国际儿科学杂志，2019，46（5）：364-366.
[3] 宋春美.小儿重症肺炎支原体肺炎的甲泼尼龙琥珀酸钠治疗体会[J].海峡药学，2019，31（6）：168-169.
[4] 肖俊华，牛玉红.甲强龙用药剂量对重症小儿支原体肺炎患儿疗效及安全性的影响分析[J].罕少疾病杂志，2020， 27（5）：16-17，20.
[5] Wu H，Ding X，Zhao D，et al. Effect of montelukast combined with methylprednisolone for the treatment of mycoplasma pneumonia [J]. J Int Med Res，2019，47（6）：2555-2561.
[6] 曹佳颖，潘家华.儿童重症支原体肺炎的诊断与治疗[J].中华全科医学，2018，16（11）：1777-1778.
[7] 蔚变霞.甲泼尼龙琥珀酸钠联合阿奇霉素治疗小儿重症支原体肺炎疗效及其对免疫功能的影响[J].中国基层医药，2020，27（3）：331-334.
[8] 赵力力，吴艳玲，冯丽娟，等.甲泼尼龙联合阿奇霉素治疗小儿重症支原体肺炎临床评价[J].中国药业，2019，28（10）：52-55.
[9] 焦媛媛.大剂量甲泼尼龙琥珀酸钠辅助阿奇霉素对肺大叶实变性重症肺炎患儿伴支原体肺炎的疗效评价[J].抗感染药学，2019，16（11）：1997-1999.
[10] 杨才千.甲泼尼龙琥珀酸钠辅助治疗儿童重症肺炎支原体肺炎的效果及对患儿肺功能、免疫状态的影响[J].中国实用医刊，2019，46（3）：102-105.
[11] Sun LL，Ye C，Zhou YL，et al. Meta-analysis of the Clinical Efficacy and Safety of High- and Low-dose Methylprednisolone in the Treatment of Children With Severe Mycoplasma Pneumoniae Pneumonia [J]. Pediatr Infect Dis J，2020，39（3）：177-183.
[12] 韩五文.甲泼尼龙琥珀酸钠联合阿奇霉素治疗重症肺炎支原体肺炎患儿的临床疗效及安全性[J].医疗装备，2019，32（20）：128-129.
[13] Qu X，Xu Z，Lin X. Effects of different doses of methylprednisolone on TNF-α，IL-6，and IL-13 in serum and bronchoalveolar lavage fluid of children with severe mycoplasma pneumoniae pneumonia [J]. J Biol Regul Homeost Agents，2020，34（5）：1889-1895.
[14] 孙宗强.甲泼尼龙琥珀酸钠与阿奇霉素联用对重症肺炎支原体肺炎患儿的临床疗效与安全性评价[J].抗感染药学，2018，15（11）：1998-1999.
[15] 孙京革.甲泼尼龙琥珀酸钠治疗小儿重症支原体肺炎的最佳剂量探究[J].中国现代药物应用，2020，14（2）：134-136.
[16] Yang EA，Kang HM，Rhim JW，et al. Early Corticosteroid Therapy for Mycoplasma pneumoniae Pneumonia Irrespective of Used Antibiotics in Children [J]. J Clin Med，2019，8（5）：726.
[17] Lee H，Yun KW，Lee HJ，et al. Antimicrobial therapy of macrolide-resistant Mycoplasma pneumoniae pneumonia in children [J]. Expert Rev Anti Infect Ther，2018，16（1）：23-34.
[18] 李竹松.阿奇霉素联合甲泼尼龙琥珀酸钠治疗重症支原体肺炎的效果观察[J].河南医学研究，2018，27（19）：3573-3574.
[19] 周天祎.加味五虎汤对小儿支原体肺炎患儿IFN-γ、IL-10水平的影响[J].光明中医，2020，35（14）：2175-2177.
[20] 王莉萍.难治性肺炎支原体肺炎患儿血清炎症因子表达的变化情况研究[J].临床研究，2020，28（2）：90-92.
[21] 王振，刘志国，刘风颍.布地奈德、孟鲁司特钠联合治疗肺炎支原体肺炎患儿疗效及对炎性细胞因子的影响分析[J].中国保健营养，2020，30（1）：313-314.
[22] Smith NM，Wasserman GA，Coleman FT，et al. Regionally Compartmentalized Resident Memory T Cells Mediate Naturally Acquired Protection Against Pneumococcal Pneumonia [J]. Mucosal Immunol，2018，11（1）：220-235.
[23] Jiwoon J，Ikjae K，Seeun K，et al. Comparison of 3 vaccination strategies against porcine reproductive and respiratory syndrome virus，Mycoplasma hyopneumoniae，and porcine circovirus type 2 on a 3 pathogen challenge model [J]. Can J Vet Res，2018，82（1）：39-47.
[24] 薛宝强，王廷智.支原体肺炎患儿的机体炎症反应、Th1/Th2免疫应答评估及其与病原菌负荷的相关性[J].海南医学院学报，2018，24（3）：338-341.
[25] 郭飞波，韩利蓉，余卉，等.血清补体、免疫球蛋白及炎性细胞因子动态检测在儿童肺炎支原体感染中的应用价值[J].中国免疫学杂志，2017，33（6）：910-913，918.
[26] 朱艳丽.阿奇霉素联合甲泼尼龙治疗小儿难治性支原体肺炎价值体会[J].中外医学研究，2019，17（8）：27-28.
[27] 周婷.甲泼尼龙琥珀酸钠辅助治疗儿童重症肺炎支原体肺炎的疗效评价[J].中国现代医生，2020，58（21）：75-77，81.
京公网安备 11010502046598号